Current News

Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome

Proteolix, Inc. discovers and develops pharmaceutical products that target certain cancers and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. Our lead product candidate, carfilzomib (PR-171), is currently in multiple clinical trials to evaluate its safety and efficacy for the treatment of multiple myeloma, lymphoma and certain solid tumor malignancies.  In addition, Proteolix is developing next generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this new target class. Proteolix is privately-held and headquartered in South San Francisco. View Corporate Profile.